Key result
PPAR alpha V allele linked to ~96% greater ACS risk versus L/L homozygotes.
Why the study?
The study was designed to clinically evaluate the relationship between peroxisome proliferator-activated receptor alpha and gamma gene polymorphisms and ACS.
Are PPAR alpha L162V and PPAR gamma C161T gene polymorphisms associated with acute coronary syndrome?
Case-Control (n=200)
No
Are PPAR alpha L162V and PPAR gamma C161T gene polymorphisms associated with acute coronary syndrome?
PPAR alpha L162V and PPAR gamma C161T gene polymorphisms are significantly associated with an increased risk of acute coronary syndrome.
OBJECTIVE: This study aims to evaluate the relationship between peroxisome proliferator-activated receptor (PPAR) alpha and gamma gene polymorphisms and acute coronary syndrome (ACS) clinically. SUBJECT AND METHODS: Peripheral blood samples were collected from a total of 200 people, including 100 acute coronary syndrome patients and 100 controls aged 19 to 93 years, admitted to the Pamukkale University Emergency Medicine Department. The healthy volunteers had no known chronic or acute diseases, no history of drug use, and no recent history of coronary artery disease (CAD). PPAR alpha L162V and PPAR gamma C161T gene polymorphic regions were detected using DNA sequencing analyses. In addition, data collected from the hemogram and biochemical parameters and comorbidities of the patients were statistically analyzed. RESULTS: PPAR gamma C161T polymorphisms were compared between groups. The CT heterozygous rate in the patient group (74%) was higher than in the control group (7%). The T allele was more common in the patient group (0.37) compared to the control group (0.03). When PPAR alpha L162V polymorphism was compared, VV homozygous individuals were %19 in the patient group and none in the control group. The V allele was found to be statistically higher in patients with ACS (p<0.01). CONCLUSION: The findings revealed that elevated PPAR alpha L162V and PPAR gamma C161T gene polymorphisms were associated with a progressive risk of ACS.
No takes yet. Share an insight, caveat, or question.
Kemancı et al. (2022) conducted a case-control in Acute Coronary Syndrome (n=200). PPAR alpha L162V and PPAR gamma C161T gene polymorphisms vs. Healthy controls / Non-carriers was evaluated on Risk of acute coronary syndrome in carriers of the PPAR alpha V allele (V/V or L/V) compared to L/L homozygotes (OR 1.96, 95% CI 1.08-3.55, p=<0.001). Carriers of the PPAR alpha V allele (V/V or L/V genotypes) had a significantly higher risk of acute coronary syndrome compared to L/L homozygotes (OR 1.96), and the PPAR gamma C/T genotype was also significantly more frequent in ACS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: